French biotech CellProthera welcomes three exceptional talents to its executive management team
17.11.2021 18:43:00 EET | Business Wire | Press release
CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs, has strengthened its executive management team to foster the development of its main clinical program and extend it to new therapeutic indications.
Ibon Garitaonandia is appointed Chief Scientific Officer (CSO). His extensive experience in drug discovery and in the development of novel stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years’ experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the first company to receive global regulatory approval to conduct a human pluripotent stem cell-based clinical trial for Parkinson’s disease.
Henk Streefkerk, MD PhD, takes the role of Chief Medical Officer (CMO). He brings decades of leadership in clinical research to boost the strategic development of the company and advance its pipeline of novel therapeutic solutions. After graduating from the University Medical Center Utrecht, Henk worked as Clinical Pharmacologist for Organon/Schering-Plough in the Netherlands. He then joined Actelion in Switzerland before taking the positions of Translational Medicine Expert and later Senior Brand Safety Leader with Novartis in Basel. After Novartis, he worked as Medical Director and Chief Medical Officer of a biotech specialized in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO). His solid history of helping companies and start-ups to scale up in their development journey is key for CellProthera as it enters its next stage of development. A lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and tax matters. He held leadership positions with Ernst & Young for more than 10 years, leading financial audits and due diligence transactions for a wide spectrum of industrial firms and as CFO, supporting the cash and financing management of listed companies in the energy and car industry.
“The arrival of these three talents - all experts in their field - in the executive management team is a great boost to our ambitious, multi-indications development program and position us ideally to accelerate our pathway to market.", stated Matthieu de Kalbermatten, Chairman of CellProthera. “The wealth of their international experience will be useful to shape and steer the company effectively during the next clinical and regulatory stages.”
CellProthera develops a medical innovation that enables a heart damaged by a heart attack to regenerate by injecting stem cells originated from the patient's own blood.
As such, each patient becomes his own source of medicine!
The stem cell product ProtheraCytes® is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future treatments that are often severe, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/fr/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006054/en/
Contact information
Press contact: Mediatiser – Antoine Monnier / amonnier@mediatiser.tv
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network28.9.2026 11:00:00 EEST | Press release
Horizon3, the AI-Native Proactive Security Company, today announced that it has earned Cyber Essentials Plus certification covering its NodeZero AWS EU network. The network supports Horizon3’s EU data sovereignty site in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928143792/en/ Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network Organizations use NodeZero® to test production environments and find weaknesses attackers can exploit. When customers and partners assess the platform itself, they also need to understand the security standards applied to its supporting infrastructure. The Cyber Essentials certificate identifies a defined portion of that infrastructure and the baseline against which it was assessed. Developed by the UK’s National Cyber Security Centre, Cyber Essentials addresses five foundational controls: firewalls, secure configuration, security updates, user access control, an
Thales Expands Collaboration with Google Cloud to Help Secure Agentic AI Workflows28.9.2026 10:03:00 EEST | Press release
Thales today announced an expanded collaboration with Google Cloud to help enterprises address emerging security and governance challenges associated with agentic AI, bringing integrated protection, visibility, and policy enforcement to AI-driven workflows on Google Cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928647188/en/ ©Thales The integration of Thales AI Security Fabric with Google Cloud Gemini Enterprise helps organizations apply security, governance, and visibility across interactions among users, agents, models, and tools in real time. “Enterprises are moving from AI assistants to AI agents that can autonomously take action, make decisions, and interact with critical business systems. This requires a fundamentally different approach to security,” Eva Rudin, Senior Vice President, Cybersecurity Products, at Thales, said.“By expanding our collaboration with Google Cloud, we are helping organizations build
SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP Fines28.9.2026 09:13:00 EEST | Press release
British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance. As the European Medicines Agency advances structured medicinal product data, companies face pressure to keep regulatory data accurate, standardised and aligned with EMA requirements. SPORVIGILANCE replaces fragmented manual assessment with a regulatory intelligence layer built around IDMP, SPOR and Product Management Service (PMS) requirements. At its core is an IDMP Business Rule Validation Engine that assesses medicinal product data at scale and at field level, identifying missing, inconsistent and non-compliant data. SPORVIGILANCE is the only platform to translate IDMP business rules directly into automated validation logic, enabling companies to test data against the rules rather than rely on manual interpretation. Its PMS Alignment capability reconciles internal RIM data ag
Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies28.9.2026 09:00:00 EEST | Press release
Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand Sofinnova's medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development. With plans to launch six to eight new medtech companies over the next five years, Sofinnova MD Start IV will support ventures from inception through key clinical and operational milestones, providing founders with both capital and hands-on support. Sofinnova MD Start's approach combines clinical insight, entrepreneurial talent, and operational expertise to tackle significant unmet medical needs. The previous fund, Sofinnova MD Start III, a €63 million fund, invested across six companies that have collectively raised more than €140 million in follow-on financing. Sofinnova MD S
Ant International’s Antom Upgrades Southeast Asia Leadership Structure to Drive Regional Synergy in the AI Era28.9.2026 08:18:00 EEST | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a series of key appointments for its operations in Southeast Asia to further strengthen the synergy among its regional brands and better serve regional merchants with streamlined full-stack AI-native solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260927431282/en/ Nabilah Alsagoff, co-founder and former chief operating officer of DOKU, Indonesia's leading payment fintech company, has been appointed as Head of Product, Antom SEA. In her new role, the payment veteran will oversee product development and innovation and drive a unified product roadmap for the overall SEA region. Chris Yeo, former chief executive officer (CEO) of DOKU, will take on the role as Head of Antom Philippines, and Country Head of 2C2P Philippines. With his long experience at DOKU, Grab and PayPal, Chris will also oversee the execution
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom